SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

/PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has been...

Related Keywords

Phoenix ,Arizona ,United States ,Chicago ,Illinois ,University Of Arizona ,Dong Zhu ,Justin Moser ,Sparx Biopharmaceutical Corp ,Sparx Group ,Research Institute ,Honorhealth Research Institute ,University Of Arizona College Medicine ,Gui Dong Zhu ,Chief Executive Officer ,Arizona College ,Sparx Biopharmaceutical ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,